176 related articles for article (PubMed ID: 16679623)
1. [BMP and osteoclastogenesis].
Nakamura M; Udagawa N; Yamamoto Y; Nakamura H
Clin Calcium; 2006 May; 16(5):809-15. PubMed ID: 16679623
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
3. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
4. [Osteoclastogenesis and bone resorption].
Nakamura M; Nakamichi Y; Nakamura H; Udagawa N
Nihon Rinsho; 2009 May; 67(5):889-96. PubMed ID: 19432105
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
6. [Regulatory mechanism of bone resorption: roles of bone remodeling-regulatory cytokines 'osteokines' in osteoclast differentiation and function].
Kobayashi Y; Takahashi N
Nihon Rinsho; 2003 Feb; 61(2):200-6. PubMed ID: 12638208
[TBL] [Abstract][Full Text] [Related]
7. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
8. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
9. [Molecules which are involved in osteoclastic bone resorption: from the aspect of targets of treatment for osteoporosis].
Take I; Takahash N; Kurihara S
Clin Calcium; 2005 May; 15(5):741-6. PubMed ID: 15876734
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
11. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
12. Current insights into the role of transforming growth factor-beta in bone resorption.
Fox SW; Lovibond AC
Mol Cell Endocrinol; 2005 Nov; 243(1-2):19-26. PubMed ID: 16219413
[TBL] [Abstract][Full Text] [Related]
13. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
Yamamoto Y; Noguchi T; Udagawa N
Clin Calcium; 2005 Jul; 15(7):11-6. PubMed ID: 15995290
[TBL] [Abstract][Full Text] [Related]
14. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) stimulates osteoclast differentiation in response to receptor activator of NF-kappaB ligand (RANKL) in osteoclast cells.
Shin HH; Kim SJ; Lee DS; Choi HS
Bone; 2005 May; 36(5):832-9. PubMed ID: 15814301
[TBL] [Abstract][Full Text] [Related]
15. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
[TBL] [Abstract][Full Text] [Related]
16. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis.
Wada T; Nakashima T; Oliveira-dos-Santos AJ; Gasser J; Hara H; Schett G; Penninger JM
Nat Med; 2005 Apr; 11(4):394-9. PubMed ID: 15750601
[TBL] [Abstract][Full Text] [Related]
17. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Regulatory mechanisms of osteoclast differentiation and function].
Takahashi N
Clin Calcium; 2006 Jun; 16(6):940-47. PubMed ID: 16751689
[TBL] [Abstract][Full Text] [Related]
18. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
19. [Prospects of treatment using interferon for bone diseases].
Iba K; Takada J; Yamashita T
Nihon Rinsho; 2006 Jul; 64(7):1275-80. PubMed ID: 16838644
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL.
Kotake S; Nanke Y; Mogi M; Kawamoto M; Furuya T; Yago T; Kobashigawa T; Togari A; Kamatani N
Eur J Immunol; 2005 Nov; 35(11):3353-63. PubMed ID: 16220542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
